Biofrontera Inc.
Biofrontera Inc. (BFRIW) Stock Overview
Explore Biofrontera Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.7M
P/E Ratio
-0.53
EPS (TTM)
$-1.30
ROE
-2.16%
BFRIW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Biofrontera Inc. (BFRIW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.01.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.53 and a market capitalization of 6.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Hermann Luebbert
92
120 Presidential Way, Woburn, DE
1970